ejpmr, 2024, 11(1), 121-129

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

MESOPOROUS SILICA NANOPARTICLES AS PROMISING NANO CARRIERS- AN OVERVIEW

Pasam Jyothirmayi*[1], Abbineni Anusha[1], V. Sushma[2], V. Sirisha[2], K. Sravani[2], G. Nagalakshmi[2] and B. Kalyani[2]

[1,2]Department of Pharmaceutics, Vikas College of Pharmacy, Vissannapeta, Krishna Dist.

***Corresponding Author: Pasam Jyothirmayi**

Department of Pharmaceutics, Vikas College of Pharmacy, Vissannapeta, Krishna Dist.

Article Received on 13/11/2023 **Article Revised on 04/12/2023** **Article Accepted on 24/12/2023**

ABSTRACT

Mesoporous silica nanoparticles (MSNs) are silica nanoparticles with large surface area and pore volume have attracted considerable attention for their application in drug delivery and biomedicine. MSN's have wide applicability as immediate, sustained, controlled and targeted drug delivery systems. The structure, morphology, size, and surface properties of MSNs have been found to be facilely tunable for the purposes of drug loading, controlled drug release and delivery, and multi fuctionalization. Meanwhile, the characteristics, various factors of MSN's, drug loading and synthesis methods and evaluation are the major parameters to study MSN's as drrug carriers. MSN's have biosafety and in vivo drug efficiency of MSN-based nano drug delivery systems (nano-DDSs), involving biocompatibility and pharmacokinetics (including biodistribution, biodegradation, retention, excretion, blood circulation) are also drawing increasing attention because of their clinical application prospects. Herein, we review the most recent research applications about MSNs.

KEYWORDS: Nanoparticles, Mesoporous silica nanoparticles, Cancer, Nanocarriers.

INTRODUCTION

Nanoparticles have dimension below 0.1 um or 100nm**,** affects the bio availability and bio distribution of particle it is useful as a drug carriers for Targeting purposes. Mesoporous silica nanoparticles (MSNs) are silica nanoparticles with pores that range in diameter from 2 to 50 nm and have an overall diameter below1µm. Their range of pore sizes is consistent with the IUPAC definition ofmesoporous[1] and make them ideal materials for applications ranging from catalysis and environmental chemical removal to biomedicine. Mesoporous silica materials were discovered in 1992 by The Mobile oil Corporation have received. They have considerable attention due to their superior textual properties such as high surface area.[1,2] Depending On The delivery route There are many types oral, transdermal administration, lung inhalation, Mucosal administration and intravenous injection.



Figure 1: Mesoporous silica nanoparticles.

Merits

- High pore volumes & surface area
- Tunability of size & Shape
- High loading Capability.
- High bioavailability
- Well-defined Surface properties
- Porous silica based material are among The most beneficial compound which Can provide more oppourtunites for treatment of cancer Therapy and provide apathway Towards The Treatment of Challenging disease.[3,4]
- MSN's as TDDS does not involves the passage

through the gastro-intestinaltract. There is no loss due to firstpass metabolism



Figure 2: Merits Of MSN's.

- **MSN have ordered porous structure.,** a Long range ordered without inter connection between individual porous Channel, which allows-fine Control of the drug loading and release kinetics.
- **High pore volume and surface area:** The pore volume and surface area of MSN are really above 700cm and respectively showing high potiential for Molecule Loading and dissolution Enhancement
- **Tunable particle Size**: The particle Use of MSN can be controlled from 50 to 300mm it is suitable for endocytosis by living cells.[5]
- **Two-functionalsurface**-MSNs have two functional Surface Namely cylindrical pore Surface Exterior Particle Surface These Silanol-containined surface can selectively functionalized to acheive better control over drug loading and release.
- **Goodbiocompatability:** Silica is generally recognized as sate by The united state food and drug administration Recently, silice nano particles in the form. of cornelldots.

Demerits

- Elimination by urine increase with the particle size affecting the degradation rate and the bio compatability.[6,7]
- Difficult inpreparationofwellordered
- Scatteredsizedistribution.
- Formulationofstable-collidalsuspensionischallenging.
- The major disadvantage of porous silica nano particle is attributed to the Surface density of silanol groups. interacting with the surfaceto the phospholipids of red blood cells Membranesresultingin hemolysis of cells.
- AnotherdisadvantgeisrelatedtometabolicChargesinducedbyporoussilicananopractical heading to melanoma promotion.

Factors affecting and characteristics of MSN's

The three Main Elements that form the Heart of MSN includes a Silica precursor tetraethyl Orthosilicate Silica Methyl Ortho Teos, tetra Methyl Ortho silicate. TMos Tetrasilicate TMVS, Sodium Meta-SilicateandletrakisCa Hydroxyethyl)! SilicateTHEOS) Surfactant)) as a Structure and directing agent SDA and & Catalyst In Cider to Ensure the Scale upMSNS all Reasonable Cost, natural perlite Materials like pumice. Rock, Rice, husk and Renewable biomass Could also be explored for the synthesis of MsNs.[8,9]

1. Control of particle size
2. Control of pore size, pore volume and mesostructure ordering
3. Control of shape
4. Drug loading release of drugs from MSNs

1. Control of particle size

ParticlesizeisveryimportantfeaturesforthebiochemicalapplicationofmsNsasdrugcarriers hence carefully turning of particle size is essential for effective drug delivery. pH of the reaction medium plays a vital role in governing the size of msNs. These agent's alter the hydrolysis and condensation of silica presscor.[10] They accelerate the reaction kinetics thus resulting in particles of smaller size. When the molar ratio of TEOS was changed from 1:1 1:4 the largest particles size was observed with the ratio 1:4.

2. Control of pore size, pore volume and the mesostructure ordering

Depending on the type of surfactants the pore size of MSNs can be varied. The longer chain length of surfactants results in MSN'S with larger pores and those with short length gives MSN's with smaller pores. The conc of TEOS inflicted the ordering of the particle. They obsessed that neither the reaction temperature nor the time showed any influence on the particle size of MSNs.[11,12]

3. Control of shape

The shape of the MsN's greatly affects the cellular uptake and bio distribution of the msNs A clearpictureoftherelationshipbetweenparticleshapeandcellularresponsewasdemonstratedBy carefully controlling the reaction conditions, non spherical materials with rod ellipsoid film, platelet sheet and cube shapes be generated. They are such as hydrogen bonding hydrophobic interactions between the organoalokoxysilcane and the surfactant.[13]

4. Drug loading and release of drugs from MSNs

The unique features of MSNs which makes it a widely exploited carries for drug deliveryit high loading

capacity due to the large pore volume and surface engineering properties.

Drug loading

- The drug is mainly based on the adsorptive properties of MSNs
- Both hydrophilic and hydrophobic carries can be incorporated into the pores of MSNs
- OwingtotheirlargeporesvolumeofMSNsinherentlypo ssessgreaterloadingcapacity compared to their carries
- They increase in the drug feeding ratio was also found to have a profound influence on the loading capacity of MSN's.
- Pore swelling agents such as as alkanes ethanol triisopropyl benzene tributylamine (TOA)decaneandN -Ndecylamine(DMHA)aid poreexpansion gives a comparison of the drug loading capacity of various MSN's

Release of drugs from MSNs

- The release profile of drugs from MSNs mainly depends on its diffusion from the pores
- They can be tailored by modifying the surface of the MsNs to the biological needs
- The decisive factor responsible for controlling the release is the interaction between the surface group on pores and the drug molecule
- Aspirin loading and release from the MSNs were studied by post –synthetic grafting as well as co-condensation method.[14]
- Echoing similar results, the release of ibuprofenfromSBA-15wasfoundtobegreatly influenced by the surface modification
- The release of ibuprofen up to3dayswasobserved presents the comparison of released rates of different of MSNS

Drug loading methods



Figure 2: Drug loading of MSN's.

MECHANISM OF FORMATION OF MSNs

A proper understanding of the MSN formation mechanism is necessary to produce particles with the correct drug delivery capabilities. According to the described process of MSN creation, non-ionic surfactant liquid-crystalline phases are where the silica network is created. According to the stated mechanism, either the hydrolyzed silica is adsorbed around the micelles or, as is the case with SBA-15, the silica and surfactant interact at the beginning and create a core shell-like structure.[15] Since then, research teams have worked to identify the precise process that gives rise to MSNs. The development of MSNs has been assessed using time-resolved small-angle neutron scattering (SANS) in situ.[16] They were able to predict the changes occurring at the same time as formation using this technique. It has been found that the silicate ions have a tendency to adsorb around the surfactant micelles during the development phase of the early hydrolysis of the silica source tetramethyl orthosilicate (TMOS). Due to the initial hydrolysis and precipitation of the silica precursor, the charge around the surfactant is reduced. This reduction in intermicellar repulsion facilitates the further formation of small aggregates of silica.[16] contain enough discrete hexagonally ordered mesopores of silica after about ~ 400 s using this technique, which was supported by TEM studies. This is consistent with the "current bun model," which was originally put forth as the mechanism by which MSNs are formed.[17]

MESOPOROUS SILICANA NOPARTICLE SYNTHESIS

In last few years mesoporous silica Nano particles have been synthesized with multiple dimensions pore sizes, pore structure and morphologies. MSN's can be synthesized by multiple adjustment in synthesis conditions like pH change using different surfactant or co-polymers and with different concentration and source of silica. In the synthesis of an ideal MSNS the characteristics like well suspended stable solution, controlled and uniform particle size, controlled pore sizes and large pore volume.[18,19]

1. Hollow silicaNano particles

Hollow silica Nano particles, is a sub-class of mesoporous silica Nano particles and is denoted by HSNs. Because of the important MSNS application in drug release and bio-sensing, hollow MSNS are prepared which increase the drug loading capacity and pore volume of the MSNs.

a) Soft templating method: Soft templating method for the preparation of mesoporous silica Nano particles is having 3 methods of synthesis.

- Single micelle-templating
- Vesicle-templating
- Micro—emulsion-templating

Single micelle-templating

Synthesised small hollow organo silica Nano tube and Nano-sphere by using sufficient amount of organo silica as a precursor and plutonic triblock copolymer with the different hydrophobicity. Mandal and kruk produced HSNS of varying sizes by using pluronic block co polymer template synthesis of ethylene-bridge organo silica in the swelling agent. Cationic block co polymer micelle used under conditions pH 7.2 at 20c for the deposition of silicate in aqueous solutions.

Vesicle-templating

Vesicle-templating method is used to further increase the size of HSNs. As a source of silica, mixture of silanes and silicates are used as well as cationic surfactant and anionic co surfactan ts are involved to lower the curvature as meso-structural template Co-condensationprocess isusedtosynthesisuniformMSNs withthesizeof25-105nm. This process involve the co-condensation of tetra ethylortho silicate and organotriethoxy silanes in an alkaline aqueous solution containing triethanolamine and cationic surfactant cetyltrimethylammonium chloride.

- **Micro—emulsion-templating**

For the preparation of hallow mesoporous silica Nano particles, stable micro-emulsion of oil-in-water is used. This emulsion is prepared by mixing oil, water, surfactant and small amount of alkaline solution. TheshollowsilicaNano-spheresarepreparedbycontrollingcondensationofsilicaga me work and silica she'll thickness Relatively large mesoporous on its outer surface ares ynthesized byHaoet at.

b. Hard templating method

In bio medical field, both discrete and mono-dispersed MSNs play a key role in providing enough stability. Physiological environment and it's Nano-size provide effective distribution of a drug in the body.

c. Polymerlatexes-templating

- On the surface of polymer latex, solidification occur through surface activation by using suitable functional group.
- Alayer-by-layerdepositiontechniqueviaelectrostaticattractiveint eractionisusedto introduce functional group of silica gelatin as a surface activation method.
- To avoid the leaching of capping agent during the process of silica deposition the strong interaction between function group and polymer latex is need.

Stober method

- The pioneer in developing a system of chemical reaction for the Synthesis of spherical mono di spares micron sizes silica particles.
- The Synthesis of MSNs can be accomplished in basic, acid and neutral condition.[20]
- Manipulatethereactionparametersresultedinparticles withdifferentshapesandsizes.
- TheSynthesiswasfirstmodifiedbygrubetatsurfactantra therthanahexagonalMCM- 41structure.

One-pot drug loading

- Drug encapsulation in whichApI isloaded into the mesoporous carrier drug during it's Synthesis.
- TheobtainedMSNsareloadedwithatargetdrugby oneoftheavailablemethod Solvent free method
- Compare to well methods, solvent-freemethod are less time -consuming and can achieve a high degree of drug loading
- Moreover, the drug concentration in the mesoporous material used is easy to predict as it is directly influenced by the ration between ApI and MSN.

Undoubtedly,theyareenvironmentallyfriendlytechniques, astheydon'trequirechecking the residual solvent in drug products, and they are located in the streams of zero waste micro -wave irradiation method.

- Loaddrugintosilicamaterialsinthistechnique,thetemp eratureduringtheloadingprocess of the API into silica nanoparticles and protects the drug from degradation
- Water et al., Used this method to load fenofibrate into a veriety of silicate including SBA- 15and compared them to samples loaded by more traditional heating method.

Porous silica method

Poroussilicawaspatentedbyvariousbygroupsinthe1960,s,r esulting in fibers as well as porous particles containing a crystallized phase with exposure to surfactant resulting in a low bulk density. Subsequent by mobile corporation laboratories which was namedMcM-41.[21]

Amorphous silica

Amorphous silica consist of Nano-sized aggregates and of agglomerate in the micrometer- sized range. In has been used in a wide variety of industrial and consumer application including food, cosmetics, and pharmaceutical products for many decades.

- Based on extensive physical -chemical, ecotoxicology data, no environmental or health risks have been associated with these materials.
- It does not produces any toxicology effect on medicine and approved by general recognized as safe.
- Low surfactant concentration to make the structure of the ordered mesoporous strongly dependent on the interaction between the growing anionic oligomer of orthosilicicacid and cationic surfactant.
- Sol-gel method
- Micro-emulsionmethod
- Hydrothermal

Sol-gel method

TwostepsconsiderationHydrolysisandcondensationhydrol ysisproducedcolloidal particles in aqueous solution Which can be stimulated at alkaline and acidicPH

Condensation reaction takes place in which gel like3Dnetworkstructureformedby cross

- linking through silioxane bond.

This process involve the formation of under the size range of 60-1000nm.

Sol-gel process is not a multistep process, so it's time-saving process and required less excipients The replication of a surfactant liquid crystal structure and

polymerization of metal oxide precursor. Evaporation induced assembly. This method was established in 1997. It is starting by forming a homogrnous solution of soluble silica and surfactant in ethanol, water with an initial surfactant concentration of critical micelle concentration. The solvent process process will start during dip coating for increase surfactant concentration. Then driving a mixture of silica/surfactant micelle, and their further formation occur into liquid crystalline mesophases. Film process was done by using aerosol processing to direct the formation of mesoporus nanoparticles. Evaporation induced assembly is an non volatile component that csan be introduced into an aerosol droplet incorporated with MSNs.[22,23]



Figure 4: Synthesis of MSN'S by microemulsion method.

- **Micro-emulsionmethod**

➢ Micro -emulsion in this method, two solution(A and B) were prepared, firstly solution a was obtain by dissolving of 4g of PVA in 250ml Dwand 150ml ethanol during stirrings at 70c, and this was follow by addition of 0.8gofCTABtothissolution and kept stirring till a transparent solution was obtained.

➢ SolutionB,25mlTEOSaddessto20mlcyclohexaneduri ngstirring 30min further rmore, solution B was drop -wised against solution A, during stirring for another 2h in order to form the micro-emulsion state After centrifugation of the obtained mixture, the precipitation particles were dried at 70c for overnight.

- **Hydrothermal**

➢ HydrothermalSynthesissolutionofTEOSwasprepared as10mlTEOSweredissolve in80mlDWwithPH2byaddingHclandstirringfor2h.Th eabovesolutionwasplaced in an auto- clave at 180c for 24 h After that the sample was calcinated at 600c as mentioned above in method.

Evaluation of MSN's

1. Particlesize, pdi, zetapotential analysis

TheMALVERN scientific(nanoparticlesZS-90) analyser was used to measure the mean particle size PDI, and zeta potential (MV) of pure palanosetron HCl and the physical mixture of drug loaded sample formulation of using dynamic light of scattering (DLS). This is a measure of the electrical charge on the surface of the MSNs. It can indicate the stability dispersibility and aggregation tendency of the MSNs in different midias[24]

2. Nitrogenadsorption-desorption analysis

Undercontinuousadsorptioncircumstancesnitrogenadsorp tion/isothermsweremeasuredusinga surface areas and porosity analysis (Micromeritics ASAP 2020 VA.01, USA) the pure MSNs samples were degassed at 300°c for 4 hrs. At relative pressure between 0.01 and 0.30, brunaver was used to determine the BET surface area, and Barrett, Joyner, and halenda (BJH) analysis was usedtodeterminethepore size andporevolumegenerated bythe instrumentfromthedesorption branches of the isotherms.

This is a technique that uses nitrogen gas to measure the adsorption and desorption isotherms of the MSNs. It can calculate the specific surface area, pore volume.

3. Invitro drug dissolution testing

This is a test that simultates the release of drug from the MSNs in different physiological conditions. it can evaluate the dry loading efficiency, release kinetics and release mechanism of the MSNs. The right capsule(0)size capsule were choosed to fill the drug loaded mesoporous nanoparticles, using the USP type II dissolution test apparatus, LABINDIA DS 8000, India. to keep the sink conditions 2 ml sample was taken out at regular intervals and replaced with new increased to 10 ml by using a volumetric flask, and the withdrawn sample was filtered by using membrane filter.[25]

4. Materials characterisation

The Microstructure, morphology and surface area characteristics of the formed samples were observed by Transmission Electron Microscope(TEM) and BET surface area analyser. Moreover, the physico-chemical

consistence was evaluated using XRD and FTIR analyses. In details, TEM, Hitachi HF-2000, Tokyo, Japan with an accelerating voltage of 200 kV was employed to assess the morphology and diameter of the prepared MSNs samples. Particularly, few milligrams of sample was dispersed into co-solvent of distilled water and ethanol(2:3). Copper grid was soaked in the previous suspension for very short time, which was allowed to dry in room temperature before the capturing of TEM images.

5. Drug loading and release behaviour

Silica Nanoparticles (100 mg) was suspended in distilled water (100 ml) and stirred for a while and then 100mg of drug was dissolved in the silica suspension. To evaluate the invitro drug release behaviour, 100mg of drug-loaded silica nanoparticles had been soaked in 100 ml of PBS buffer solution. To analyse the amount of drug release, at different time intervals 5 ml of solution were withdrawn up to 30 days. The same volume of fresh media was added to the soaked samples in order to maintain the sink conditions. The concentration of released was further determined by UV spectrophotometer.

6. Size and morphology of the MSNs

TheeffectofPreparationofmethodsonthesizeandshapeofMSNswasinvestigatedbyTEM micrographs, which are demonstrated in based on these images, This variation is thought to be related to the change of the nucleation and growth rates of the generated MSNs of each utilized method of preparation as well as presences of polymer (micro- emulsion method) that acts as a capping agent to prevent the particles agglomeration and to maintain their spherical shapes.[26]

7. Thermal behavior of drug loaded silica

In order to evaluate the drug loading on the thermal behavior of silica nanoparticles, DTA/TGA thermography were recorded before and after drug loading. the peak detector at 90° corresponding to adsorbed water from the atmosphere, was absorbed in all samples ,but it was more pronounced for the drug–loaded silica nanoparticles showed characteristics single melting endothermic peak at 230° c. Further more the tg temperature for the drug free silica nanoparticles was detected at broad exothermic peak in the range of 300-550°c. The peak was shifted and broadentotherangeof525-660°c in the case of drug loaded silicananoparticles further more, the TGA results exhibited weight loss percent(%) consistence with the DTA results. the total weight

Loss of the drug loaded silica nanoparticles at the end oftherunwas1.12%compared to the drug free silica nanoparticles indicating the presence of the drug.

8. Drug release behaviour

The amount of drug released into the PBS buffer solution was determined by UV spectrophotometer. The cumulative drug release (%CDR) profiles of drug released from MSNs formulations are shown in Figure6. From the release profiles it was revealed that, there is an obvious difference between release rates of all drug-loaded samples. Comparing the release behavior of the prepared samples as a main factor of the current research, the ability of nanoparticles to control drug release, are clear to be adjusted by various parameters. This behaviour could be interpreted owing to the size of the pores is much bigger than the drug molecules, which means that most of the drug molecules will be adsorbed onto the surface of MSNs. This would cause the carried drug molecules to be released at relatively higher rates. Ideally, it is hypothesized that the sustained release of drug could be achieved when the carried drug molecules and pore diameter are approximately the same size.

Mesoporous silica nanoparticles applications

Mesoporous silica nanoparticles are used in

- Bioavailability improvement.
- Chemical and pharmaceutical purification.
- Surface Affinity improvement.
- Water purification.
- Targeted and controlled drug delivery system.
- For biosensing cell imaging and diagnostic-imaging
- In gene and peptide delivery.
- Wound healing
- Tissue engineering
- Dispersibility

Improving Bioavailability

Low density porous carrier such as porous silicon dioxide (sylysia), polypropylene foam powder(Accurel), porouscalciumsilicate(Florite), magnesiumaluminometasilicate(Neuslin) and porous ceramic, with open or closed pore structure, provide large surface areas and are used for improving the dissolution and bioavailability of poorly soluble drugs such as meloxicam, Aspirin and indomethacin. Randy Mellaerts et al. reported that ordered mesoporous silica (OMS)is a promising carrier for achieving enhanced Oral Bioavailability of drugs with poor aqueous solubility. It investigated the effects of spherical MSNs as an Oral drug delivery system (DDS) to improve the oral bio-availability of the model drug TEL and examined their cellular uptake and cytotoxicity.

Chemical and pharmaceutical Purification

Adsorption in carbonaceous adsorbent is suitable for declorization and Purification of a wide range of Organic and inorganic compounds including amines, hydrochloride and other mineralacids, aminoacids, glycolsandhydrocarbons. Catalystcanbepoisonedor founded by low concentrationorganiccompounds, sulfur, ormercuryspecies. Carbonaceousmaterial, ofbothnon impregnated and impregnated types, are typically used as" guard beds" to protect the catalyst and the equipment in streams such as natural gas, acetylene, ethane, propane, and ethylene oxide. Adsorption in carbonaceous adsorbent is widely used for declorization of natural and

synthetic sweetener, came sugar, syrup, and vitamins purification of Glycerin.

Improving surface Affinity

Otsukaetalinvestigatedthesurfacemodificationofsilicagel withsilanecouplingtoimprove affinity to an oily medicine, phytonadione. However, a rapid release, especially an initial brust release, has been observed in some cases when inorganic porous particles have been used as the drug host.

Water purification

Mesoporous silica nanoparticles are emerging as promising adsorption materials for water purification applications because of their surface area, tunable structure and surface property. It low affinity with some contaminats limit the wide spread technology adoption. Surface functionalize of MSNs with different functional group enhanced the chemical interaction with target water pollutant. Result suggest that the modified MSN exhibited improved chemical affinity and adsorption capacity and are promising adsorbents in water purification.[27]

Targeted and controlled Drug Delivery

All relatively new field of medicine call drug delivery includes the use of various therapies. Therapeutic Agent is delivered using nanoscience and nanotechnology with singular system. Mesoporous silica nanoparticles have unique qualities that make ideal nano carrier for storing, safe guarding and delivery medication to the intended location. MSN are frequently used in the adsorption of toxic molecules due to their large surface area, selectively of adsorption substance and minimal toxicity. Cancer target therapy has been the main focus of study of mesoporous silica for drug Delivery.

Specific targeting is a highly appealing for identifying the site of a disease diagnostics on it's own. As a result this technique reduces the dosage of drug Administered and lessens their toxic side effects while in Administration. Different functinalization and conjugation are done with MSNs to provide smart drug delivery system. The drug release rate can be retarded by modifying the function alization of surface drug. Moreover drug targeting can be facility at ed by suitablesur face Functinalization. **Example,** folicacid conjugation for cancer cell targeting Photodynamic therapy can also be employed to are cancer and other infection disease by passive targeting.

Mesoporous silica nanoparticles can be used on the intended areas to reduce non specific binding and to increase specific Dispbinding to target cell or tissue. Both passive and active targeting specificity plays a major role in increasing bioavailability. Target specificity of mesoporous silica nanoparticles decrease the dosage of drug and harmful toxic effects of drug after administration. Positive targeting increase permeability of tumor blood vessels and allow the accumulation of nano carrier at tumor site. Binding and internalization of nano carrier can be Increase by selective targeting i.e. specific interaction of drug with receptor site. Inactive targeting, surface modification of MSN with cancer specific targeting drugs increase the specificity of drug to the cancer cells as compare to normal healthy cells.[28]

Traget specific in Tumor

Cancer is significant cause of morbidity in human. The most crucial aspects of chemotherapy is the use of different chemical entities to induce apoptosis. Given the deficiency of selectively of chemo therapeutic agents, severe adverse effects can be induced. In addition, toxicity, conventional chemotherapy, also suffers from the poor solubility of hydrophobic drugs, fast systematic elimination and multi drug resistance.

Mesoporous silica nanoparticles can be used in cancer therapy to enhance specific binding to receptors of Target cells or tissue while decreasing non specific binding to those same receptors. Passive and active target specialisation is crucial for boosting Bioavailability. Drug permeability in tumour blood vessels is increase by passive target specificity, which also permits the build up of nanocarrier at the tumour site. Selective targeting can improve the specificity of drug interaction with the receptor site of binding and the internalisation of nanocarrier.

Biosensing, cellimagingand diagnosticimaging

Mesoporous silica nanoparticles are used as biosensing element due to their size and versatile chemistry of the structure. Nanoparticles do not suffer from fluorescent, self quenching, other diffusionrelatedproblems. Mesoporous silica nanoparticles are used as device for the invivo and invitro detection to target within individual cells. This capability of mesoporous silica nano particles to functionalizeit's surface with greater amount of cell recognizing agents or other site directing compounds makes MSN an excellent cell tracing agent.

Due to its hydrophilic surface and ability to be easily distributed on aqueous solution, MSNs are used as imaging Agents. It is perfect platform for biomedical imaging and diagnositic application because of the broad range and quantity of compounds that are included in their stability and their manageable size.

In Recent years, multifunctional nanomaterials are used for simultaneous imaging and therapy. silica based imaging nanoprobes are most commonly used for optical, magnetic resonance imaging combination of both modalities. Silica nanoparticles are can excellent carrier for facile loading of a wide variety of imaging and therapeutic moieties, making them promising candidates for therapeutic applications.

Gene and peptide Delivery

Various development have taken place in this context using different functinalization, different gases, different

Tigger mechanism in the study of specific molecules like gene, proteins and peptides. The targeted specific delivery of the gene to the selected cells is the most important challenge in gene delivery. In general, gene delivery vectors can be classified in two categories in 1.viralvectors and 2.nonviralvectors.

Wound healing

Mesoporous silica has found its application in this field as well. Commonly available options for the fast giving of tissue are fibrin glue, cyano acrylate adhesive. The problem associated with the cyanocrylate adhesive is the immune genic reaction of serve heat produce the point of application and the damage of tissue may take place at this site. Nanoparticles have the ability to glue together the tissue by nano bridging effects. They concluded that is wound closed in 30 sec whileithealedin 5days. Biodegradablilitywasalsoconfirmedwhichtookplacecomp letelyin96 hrs. It could be significantly promote the blood clot. Rapid haemostatis of MSNs in Rabbit artery injury testified the superb haemostatic efficacy in MSN.[29]

Tissue engineering

Most of the research on MSN in tissue engineering has focused on osteogenic differentiation and bonet issue formation. One of the demonstration of MSN sint issue engineering was the attachment of MSNs on titanium substrates by layer by layer assembly as implant technology. The modified surface improved the behaviour of osteoclasts. MSNs have been show improve the tensile mechanical properties of poly-lac-tic-co-glycolic acid fibresinhydrogel which important for re generations of hard tissue. Dexamethasone loaded with MSNs to which Bone morphogenetic protein-2 peptide was covantely grafted improve osteogenic differentiation of mesenchymal stem cells. The particles were designed for targeted cancer delivery to avoid this particular side effect of inhibition. The demonstrated delay cell target delivery by MSNs using aflu modeldrug and showed that the cell infiltrated scaffold could be vascularized in Vivo, which is important to support tissue development and functions. The field is only emerging, and currentlyrestrictedtofewapplicationsandweareanticipating arealisationsofthepowerofMSNs to control drug delivery, to image cells and molecular process for tissue engineering.

Dispersibility

For biomedical applications MSN must remain dispersed for its stability and it aggregation must be avoided because to this cell internalization suffers, it's distribution in body become difficult control and enlarge particlesize cause high toxicity. By using these methods sterichendrance and electrostatic repulsion is achieved, as a results tables aline dispersion of MSN. OtherApplications include biosensing and cell tracing use Inoptoelectronic device, cdsnanoparticles –capped MSNs use for delivery of drug molecules/ neurotransmitters In addition, most antitumor drugs demonstrate poor water solubility, poor permeability across biological membranes, inadequate bioavailability that restrict their administration by intravenous or oral routes.[30]

Active surface Decorations

Surface Decorations with targeting ligands efforts have been made to functionalize the surface of MSNs with cancer –specific targeting ligands for enhanced MSNs take by cancer cells compared to non cancerous cells. Besides folic acid, other small cell nutrients molecules such as mannose and other drugs were also shown to selectively improve the uptake of MSNs by breast cancer cells.

CONCLUSION

Mesoporous silica nanoparticle drug delivery systems are effective due to their structural properties, high drug loading capacity, biocompatibility, cost effective synthesis, and use of these nanomaterials as delivery systems for biological cells and targeted releases. In order to effectively transport and distribute extremely toxic drugs, such as chemotherapeutic agents for cancer treatment, MSNPs as promising nanocarriers. In conclusion, this review goes into great depth about the most recent developments in the synthesis and functionalization of MSNs. MSNPs are promising nanocarriers to efficiently transport and site-specifically deliver highly toxic drugs, like chemotherapeutic agents for cancer treatment. MSNs are efficiently transported site specific drug delivery of highly toxic drug such chemotherapeutic agents for effective cancer treatment. They have stimuli responsive drug releases so, it enhancing and minimizing the side effects of anti-cancer drugs in cancer therapy.

REFERENCES

1. Lin X, Xie J, Niu G, Zhang F, Gao H, Yang M, et al. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. *Nano Lett.*, 2011; 11: 814–9.
2. Poklar Ulrih, Nataša. "Analytical techniques for the study of polyphenol–protein interactions." Critical Reviews in Food Science and Nutrition, 2017; 57(10): 2144-2161.
3. Fruijtier-Pölloth C. The toxicological mode of action and the safety of synthetic amorphous silica-a nanostructured material. *Toxicology.*, 2012; 294: 61–79.
4. Chircov, Cristina, Angela Spoială, Cătălin Păun, Luminița Crăciun, Denisa Ficai, Anton Ficai, Ecaterina Andronescu, and Ștefan Claudiu Turculeț. "Mesoporous silica platforms with potential applications in release and adsorption of active agents." Molecules, 2020; 25(17): 3814.
5. Vivero-Escoto JL, Luis J. Surface functionalized mesoporous silica nanoparticles for intracellular drug delivery. *Diss Abstr Int.*, 2009; 71: 621–38.
6. C Thomas, Shindu, Pawan Kumar Mishra, and Sushama Talegaonkar. "Ceramic nanoparticles:

fabrication methods and applications in drug delivery." Current pharmaceutical design, 2015; 21(42): 6165-6188.
7. Tang, F.; Li, L.; Chen, D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. *Adv. Mater.*, **2012;** *24:* 1504–1534.
8. Limo, Marion J., Anna Sola-Rabada, Estefania Boix, Veeranjaneyulu Thota, Zayd C. Westcott, Valeria Puddu, and Carole C. Perry. "Interactions between metal oxides and biomolecules: from fundamental understanding to applications." Chemical reviews, 2018; 118(22): 11118-11193.
9. **S**wamiA, JinjunS, sureshG, votruvaAR, Nagesh K, farokhzad nanoparticles for targeted and temporarily controlled drug delivery. In: svenson S, Vruds homme RK, editors. multifunctionalnanoparticlesfordrugdelivery, applications:imaging, targeting, anddelivery, nanostructuresciencetechnology, 1998; 368: 390.
10. Shahbazi, Mohammad-Ali, Leila Faghfouri, Mónica PA Ferreira, Patricia Figueiredo, Hajar Maleki, Farshid Sefat, Jouni Hirvonen, and Hélder A. Santos. "The versatile biomedical applications of bismuth-based nanoparticles and composites: therapeutic, diagnostic, biosensing, and regenerative properties." Chemical Society Reviews, 2020; 49(4): 1253- 1321.
11. Martínez-Carmona, M.; Colilla, M.; Vallet-Regí, M. Smart mesoporous nanomaterials for antitumor therapy. *Nanomaterials,* **2015;** *5:* 1906–1937.
12. KresgeCT, leolowiczME, RothWJ. Ordered mesoporousmolecularsievessynthesizedbya liquid -crystaltemplatemechanismnature, 1992; 359: 710.
13. LiC, Wang J, wangY, gaoH, weiG, huangY, etal. Recent progress in drug delivery Acta pharmsin B., 2019; 9(6): 1145-62.
14. Kankala, Ranjith Kumar, Ya Hui Han, Jongbeom Na, Chia Hung Lee, Ziqi Sun, Shi Bin Wang, Tatsuo Kimura et al. "Nanoarchitectured structure and surface biofunctionality of mesoporous silica nanoparticles." Advanced materials, 2020; 32(23): 1907035.
15. Rosenholm, J.M.; Mamaeva, V.; Sahlgren, C.; Lindén, M. Nanoparticles in targeted cancer therapy: Mesoporous silica nanoparticles entering preclinical development stage. *Nanomedicine,* **2011;** *7:* 111–120.
16. Martínez-Carmona, M.; Lozano, D.; Colilla, M.; Vallet-Regí, M. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. *Acta Biomater,* **2017;** *65:* 393–404.
17. Bagshaw S, Bruce I. Rapid calcination of high-quality mesostructured MCM-41, MSU-X, and SBA-15 silicate materials: A step towards continuous processing? Micropor Mesopor Mat., 2008; 109: 199–209.
18. Liu, Y.; Qiao, L.; Zhang, S.; Wan, G.; Chen, B.; Zhou, P.; Zhang, N.; Wang, Y. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. *Acta Biomater*, **2017**, in press.
19. Florensa, Marta, Marina Llenas, Esperanza Medina-Gutiérrez, Stefania Sandoval, and Gerard Tobías-Rossell. "Key Parameters for the Rational Design, Synthesis, and Functionalization of Biocompatible Mesoporous Silica Nanoparticles." Pharmaceutics, 2022; 14(12): 2703.
20. Gallis K, Landry C. Rapid Calcination of Nanostructured Silicate Composites by Microwave Irradiation. Adv Mater, 2001; 13(1): 23-26.
21. Voycheva Ch, Georgiev V, Natova M, Baranovsky V. Preparation, Modification and Characterisation of a Hydrogel Based on Polyacrylic and Polymetacrylic Acid as a Potential Carrier for Drug Delivery Systems. OAJPR, 2017; 1(2): 000112.
22. Baeza A, Colilla M, Vallet-Regí M. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery. *Expert Opin Drug Deliv.*, 2015; 12: 319–37.
23. Yoncheva K, Popova M, Szegedi A, Mihály J, Tzankov B, Lambov N, Konstantinov S, Tzankova V, Pessina F, Valoti M. Functionalized mesoporous silica nanoparticles for oral delivery of budesonide. J Solid State Chem., 2014; 211: 154-161.
24. Cheng, S.-H.; Lee, C.-H.; Chen, M.-C.; Souris, J.S.; Tseng, F.-G.; Yang, C.-S.; Mou, C.-Y.; Chen, C.-T.; Lo, L.-W. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics—The trio of imaging, targeting and therapy. *J. Mater. Chem.*, **2010;** *20:* 6149–6157.
25. Chen Y, Meng Q, Wu M, Wang S, Xu P, Chen H, Li Y, Zhang L, Wang L, Shi J. Hollow Mesoporous Organosilica Nanoparticles: A Generic Intelligent Framework-Hybridization Approach for Biomedicine. J Am Chem Soc., 2014; 136(46): 16326–16334.
26. Moulari B, Pertuit D, Pellequer Y, Lamprecht A. The targeting of surface-modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials, 2008; 29: 4554–4560.
27. Baranovskii V, Ganev V, Petkova V, Voicheva Kh, Dimitrov M. Hydrogels Based on Polycarboxylic Acid– Agar-Agar Complexes. Colloid J., 2012; 74(6): 675-679.
28. Tarn D, Ashley CE, Xue M, Carnes EC, Zink JI, Brinker CJ. Mesoporous silica nanoparticle nanocarriers: Biofunctionality and biocompatibility. *Acc Chem Res.*, 2013; 46: 792–801.
29. Singh D, McMillan JM, Liu XM, Vishwasrao HM, Kabanov AV, Sokolsky-Papkov M, et al. Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. *Nanomedicine (Lond)*, 2014; 9: 469–85.
30. Colilla M, Izquierdo-Barba I, Vallet-Regi M. Phosphorus-containing SBA-15 materials as bisphosphonate carriers for osteoporosis treatment. *Microporous Mesoporous Mater*, 2010; 135: 51–9.